Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7842012 | 1.00 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL3310175 | 0.91 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL7842596 | 0.91 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL7833523 | 0.91 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL7845375 | 0.91 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL7844584 | 0.90 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL7846916 | 0.90 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL7846788 | 0.90 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL7839937 | 0.89 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL7843375 | 0.89 | PTGS2 (0.61) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1125932-A2 | Substituted thiazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2001-08-22 | — | — | EP | claimed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| EP-1125932-A2 | Substituted thiazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2001-08-22 | — | — | EP | disclosed |
| US-5668161-A | Substituted thiazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0772606-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003392-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | PTGS2 15/4885PTGS1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.